<DOC>
	<DOCNO>NCT00619710</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority meropenem ( Merrem ) imipenem hospitalise subject complicate skin skin structure infection .</brief_summary>
	<brief_title>Complicated Skin Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>Subjects hospitalize male female , age 13 year old , clinical evidence complicate skin skin structure bacterial infection material suitable culture 1 primary site infection Within 72 hour enrollment time enrollment , subject must provide appropriate specimen culture susceptibility test Subjects give prior antibacterial therapy within 14 day trial entry may enter culture obtain show persistence pathogen blood site infection Subjects know suspected hypersensitivity cephalosporin , penicillin , carbapenems Subjects history seizure disorder subject currently receive antiepileptic medication Subjects underlying infection condition would interfere evaluation study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>skin infection</keyword>
	<keyword>MERREM</keyword>
	<keyword>PRIMAXIN IV</keyword>
	<keyword>complex abscess</keyword>
	<keyword>perirectal abscess</keyword>
	<keyword>wound infection</keyword>
	<keyword>infect ischemic/diabetic ulcer</keyword>
	<keyword>cellulitis</keyword>
	<keyword>Meropenem</keyword>
	<keyword>Imipenem-cilastatin</keyword>
</DOC>